Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.2)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Open Access
Clockss

Download whole issue [PDF]

Contents – 2024, Vol. 33, No. 4 (April)

1

Editorial

The intricate brain–body interaction in psychiatric and neurological diseases

321-326

2

Meta-analysis

A meta-analysis of the risk of osteoporotic fractures in inflammatory bowel disease

327-333

3

Original Article

Clinical efficacy of conbercept injection on neovascular age-related macular degeneration under different levels of inflammation

335-342

4

Original Article

The distance between the anterior and posterior edges of the fibula at a lateral internal rotation of 15° is associated with postoperative malreduction in patients with an ankle joint fracture combined with a lower tibiofibular syndesmosis injury

343-350

5

Original Article

Preoperative prognostic nutritional index associated with anastomotic leakage in colorectal cancer patients after surgery

351-359

6

Original Article

Cytogenetic findings in Polish patients with suspected Fanconi anemia

361-368

7

Original Article

Association between clinical features and course of systemic sclerosis and serum interleukin-8, vascular endothelial growth factor, basic fibroblast growth factor, and interferon alpha

369-377

8

Original Article

Distal symmetrical polyneuropathy in diabetes mellitus patients: Proposition of a new scoring system based on electroneurography findings

379-385

9

Original Article

Changes in the scar tissue structure after cesarean section as a result of manual therapy

387-395

10

Original Article

Gene expression profile of hiPSC-derived cells differentiated with growth factors, forskolin and conditioned medium from human adrenocortical cell line

397-407

11

Review

At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?

409-418